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was no effect when our results were adjusted for maternal age and
parity.
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Table 1 Serum levels of studied hormones at 16 and 27 completed weeks of gestation among pregnant women in Boston, USA (n = 304) and in Shanghai,
China (n = 334), stratified by maternal age
Age ≤ 20 Age 20–24 Age 25–29 Age 30+
Sample 1 Sample 2 Sample 1 Sample 2 Sample 1 Sample 2 Sample 1 Sample 2
Hormone Mean Mean Mean Mean Mean Mean Mean Mean
Estradiol (E2) Boston 16.7 47.7 14.7 38.1 15.8 39.9 13.4 38.8
nmol l–1 Shanghai 17.0 – 20.7 49.5 20.3 46.9 21.9 44.8
Estriol (E3) Boston 3.01 14.3 3.7 14.6 4.1 13.5 3.7 14.1
nmol l–1 Shanghai 5.0 – 6.1 22.6 6.4 20.8 6.7 21.2
Prolactin Boston 25.9 80.1 39.2 65.2 47.2 89.6 44.0 92.4
µ g l–1 Shanghai 30.0 – 58.5 111.5 67.0 123.5 71.7 119.7
Progesterone Boston 88.6 167.0 104.9 248.3 136.3 263.5 132.6 263.9
nmol l–1 Shanghai 129.0 – 143.1 249.5 141.5 237.2 148.4 262.5
Growth hormone Boston 13.7 1.3 1.4 0.6 3.3 0.9 2.9 0.9
mU l–1 Shanghai 5.9 – 4.2 1.9 3.3 1.5 2.8 1.7
Albumin Boston 37.4 32.5 41.6 37.4 40.5 37.0 40.1 36.3
g l–1 Shanghai 44.7 – 43.6 40.0 42.8 39.1 42.3 38.9
SHBGa Boston 417.3 344.2 312.6 417.1 381.1 431.8 356.1 423.7
nmol l–1 Shanghai 447.1 – 437.7 496.4 416.0 446.9 428.4 475.0
aSex hormone-binding globulin.
Table 2 Serum levels of studied hormones at 16 and 27 completed weeks of gestation among pregnant women in Boston, USA (n = 304) and in Shanghai,
China (n = 334), stratified by maternal parity
No previous livebirths One previous livebirth
Sample 1 Sample 2 Sample 1 Sample 2
Hormone Mean Mean Mean Mean
Estradiol (E2) Boston 15.4 42.2 11.8 33.9
nmol l–1 Shanghai 20.8 48.4 17.6 39.7
Estriol (E3) Boston 3.9 14.2 3.8 13.7
nmol l–1 Shanghai 6.3 22.0 4.8 19.3
Prolactin Boston 50.4 95.9 35.0 83.5
µ g l–1 Shanghai 63.3 116.4 50.6 103.4
Progesterone Boston 135.3 269.2 129.2 253.4
nmol l–1 Shanghai 143.4 248.3 138.2 231.6
Growth hormone Boston 3.1 1.0 2.8 0.8
mU l–1 Shanghai 3.7 1.8 1.5 1.2
Albumin Boston 40.5 36.7 39.7 36.1
g l–1 Shanghai 43.1 39.6 43.2 38.8
SHBGa Boston 372.1 436.1 345.9 408.1
nmol l–1 Shanghai 429.7 478.2 414.6 518.6
aSex hormone-binding globulin.
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Sir
In a recent letter to the editor, Shamash et al (2000) argued that a
raised serum lactate dehydrogenase catalytic concentration (S-LD)
prior to induction chemotherapy for patients with germ cell tumours
predicted a poor outcome. They referred to increasing evidence for a
raised S-LD before first-line chemotherapy being as good if not
better than serum human chorionic gonadotropin concentration (S-
hCG), as found in, e.g., International Germ Cell Cancer
Collaboratory Group (IGCCCG) (von Eyben et al, 1983; Mead and
Stenning, 1997). Correspondingly, the fifth edition of the TNM (T =primary tumour, N = lymph node, M = distant metastases) classifica-
tion included S-LD, serum alpha fetoprotein concentration, and S-
hCG as serum tumour markers for testicular germ cell tumours
(TGCT) (Sobin and Wittekind, 1997). The TNM classification is
well documented and has been validated repeatedly.
LD consists of five LD isoenzymes. The literature points to a char-
acteristic S-LD isoenzyme pattern in patients with TGCT and a
raised S-LD: they predominantly have a raised S-LD isoenzyme 1
catalytic concentration (S-LD-1) (von Eyben et al, 1983). In contrast,
patients with a raised S-LD due predominantly to S-LD isoenzyme 5
catalytic concentration most likely have presence of another disease,
not TGCT. The S-LD-1 pattern in patients with TGCT reflects a char-
acteristic chromosomal abnormality in the tumours: a high copy
number of the short arms of chromosome 12, 12p, often with an
isochromosome of 12p, i(l2p) (von Eyben et al, 1992a).
We combined the results of two published series of patients with
metastatic TGCT monitored with S-LD-1 in Table 1 (von Eyben
et al, 1992b; 2000). Even though the patients were treated at two
institutions using different staging systems and treatments, the two
series showed consistent findings. 42 of 81 patients (52%) had a
raised S-LD-1 and 41 of the 42 also had a raised S-LD. However,
eight patients had a discordant pattern with a normal S-LD-1 and a
raised S-LD (Figure 1). Separated in three subgroups according to
the S-LD-1 level, the 81 patients differed markedly regarding
the survival (P < 0.00001, log-rank test, chi square for trend)
(Figure 2A). Overall S-LD, S-hCG, and the prognostic classifica-
tion of the IGCCCG study also predicted the survival (P =
0.00032, 0.02, and 0.0005, respectively, Figure 2B and 2C)
whereas S-AFP did not (P = 0.68) (Figure 2D). The subgroup of
39 patients with a normal S-LD-1 had the best survival and this
favourable survival was not influenced whether S-LD was normal
(31 patients) or raised (eight patients) (P = 0.56) (Figure 2E). Eight
patients with an S-LD-1/S-LD fraction > 0.375 had a poorer
survival than the 73 with a lower fraction (P = 0.002) (Figure 2F).
So S-LD-1 might add prognostic information even for the TGCT
patients with a raised S-LD. In one of the series, S-LD isoenzyme
5 catalytic concentration did not have a prognostic significance
(von Eyben et al, 2000). Accordingly, the prognostic implication
of a raised S-LD might be solely due to a raised S-LD-1.
S-LD-1 gave a larger difference in survival between the
subgroups of patients with the best and the poorest survival than
the IGCCCG classification. So the TNM classification for patients
with TGCT may not be the optimum usage of the available prog-
nostic information.
These observations indicate that S-LD-1 is better than S-LD to
predict the survival of patients with TGCT. However, the findings
should be validated in larger series of patients with TGCT. We
welcome interested oncologists to participate in a multicentre
study of this question.
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Table 1 Subgroups of the patients with metastatic TGCT according to S-LD-
1 and the serum S category of the serum marker levels in the fifth edition of
the TNM classification
Serum S categories Number of patients
tumour (n (%))
marker
S-LD-1 < 12 U l–1 39 (48%)
112–1120 U l–1 37 (46%)
> 1120 U l–1 5 (6%)
S-LD < 675 U l–1 53 (65%)
675–4500 U l–1 22 (29%)
> 4500 U l–1 5 (6%)
S-AFP < 999 µ g l–1 76 (94%)
1000–10 000 µ g l–1 4 (5%)
> 10 000 µ g l–1 1 (1%)
S-hCG < 4999 IU l–1 72 (91%)
5000–50,000 IU l–1 4 (5%)
> 50 000 IU l–1 5 (6%)
IGCCCG Good prognosis 49 (60%)
Intermediate prognosis 16 (20%)
Poor prognosis 16 (20%)
Serum categories cover normal, raised and very raised S-LD-1 and the
tumour marker prognostic categories of the fifth edition of the TNM
classification for S-LD, S-AFP and S-hCG. The TNM classification did not
include S-LD-1.
LD-1r&LDn
1
LD-1r&LDr
41
LD1n&LDr
8
LD1n&LDn  31
Figure 1 Venn diagram shows the association between raised levels of
S-LD and S-LD-1 for 81 patients with metastatic TGCT. LD1r&LDr denotes
41 patients with a raised S-LD-1 and S-LD and LD1n&LDn denotes 31
patients with a normal S-LD-1 and S-LD1258 Letters to the Editor
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Figure 2 (A) The survival for 81 patients with metastatic TGCT according to the initial postsurgical S-LD-1 (—— = 39 patients with S-LD-1 < 112 U L–1,
– – = 37 with S-LD-1 112–1120 U l–1, and – . – = five with S-LD-1 > 1120 U l–1). (B) The survival according to S-hCG (—— = 39 patients with S-hCG < 30 IU l–1,
– – = 33 with S-hCG 30–4999 IU l–1, - - - = four with S-hCG 5000–50 000 IU l–1, - - - = five with S-hCG > 50 000 IU l–1). (C) The survival according to the risk
groups of the IGCCCG classification (—— = 49 patients with a good prognosis, —— = 16 with an intermediate prognosis, and - - - = 16 with a poor prognosis).
(D) The survival according to S-AFP (—— = 50 patients with S-AFP < 24 µ g l–1, —— = 26 with S-AFP 24–999 µ g l–1, - - - = four with S-AFP 1000–10 000 µ g l–1,
- - - = one with S-AFP > 10 000 µ g l–1. (E) The survival according to the concomitantly normal and raised levels of S-LD-1 and S-LD (—— = 31 patients with
normal values of S-LD-1 and S-LD, — — = eight with a normal value of S-LD-1 and a raised S-LD, and - - - = 42 with a raised S-LD-1 (with or without a raised
S-LD)). (F) The survival according to the S-LD-1/S-LD ratio (—— = 73 patients with an S-LD-1 ratio < 0.375, and – – = eight with a ratio > 0.375)
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Serum lactate dehydrogenase isoenzyme 1 as a
prognostic predictor for metastatic testicular germ cell
tumours – reply
Sir
von Eyben et al describe their experience of splitting total LDH
into its various isoenzymes and have identified LDH isoenzyme 1
(S-LD-1) as having prognostic significance in untreated patients
with metastatic germ cell tumours. The evidence they present
is clearly impressive and S-LD-1 appears to be able to identify
patients with a poor outcome as effectively as the IGCCCG speci-
fication or serum HCG alone.